IRIS UniCatt

Iacovelli, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.201
NA - Nord America 967
EU - Europa 552
SA - Sud America 307
AF - Africa 37
OC - Oceania 2
Totale 3.066
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 921
SG - Singapore 519
BR - Brasile 265
CN - Cina 235
SE - Svezia 137
VN - Vietnam 136
IT - Italia 105
IN - India 91
FR - Francia 73
DE - Germania 72
JP - Giappone 40
GB - Regno Unito 38
HK - Hong Kong 37
IE - Irlanda 30
BD - Bangladesh 27
ID - Indonesia 26
MX - Messico 23
KR - Corea 16
RU - Federazione Russa 16
PL - Polonia 15
AR - Argentina 14
CA - Canada 14
IQ - Iraq 12
ZA - Sudafrica 11
ES - Italia 10
FI - Finlandia 10
NL - Olanda 10
EC - Ecuador 9
TR - Turchia 9
UA - Ucraina 8
LT - Lituania 7
SA - Arabia Saudita 7
CO - Colombia 6
EG - Egitto 6
IR - Iran 6
AE - Emirati Arabi Uniti 5
PK - Pakistan 5
VE - Venezuela 5
AT - Austria 4
CI - Costa d'Avorio 4
JO - Giordania 4
MA - Marocco 4
UZ - Uzbekistan 4
CL - Cile 3
DZ - Algeria 3
ET - Etiopia 3
HN - Honduras 3
LB - Libano 3
MM - Myanmar 3
NP - Nepal 3
PH - Filippine 3
AU - Australia 2
CZ - Repubblica Ceca 2
GR - Grecia 2
KE - Kenya 2
LU - Lussemburgo 2
MY - Malesia 2
PE - Perù 2
PY - Paraguay 2
RO - Romania 2
SI - Slovenia 2
TH - Thailandia 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AO - Angola 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BY - Bielorussia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MD - Moldavia 1
NI - Nicaragua 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SN - Senegal 1
SR - Suriname 1
Totale 3.066
Salva come PNG Salva come JPEG
Città #
Singapore 280
San Jose 139
Ashburn 127
Chandler 81
Ho Chi Minh City 63
Hyderabad 53
Hefei 50
Beijing 46
Tokyo 40
Los Angeles 37
New York 36
Hong Kong 35
Lauterbourg 32
Frankfurt am Main 31
Dublin 30
Hanoi 29
The Dalles 27
Rome 25
São Paulo 25
Jakarta 20
Seoul 16
Milan 15
Kent 14
Chicago 12
Düsseldorf 12
Mexico City 12
Orem 11
Princeton 11
Warsaw 11
Boston 10
Santa Clara 10
Houston 9
Chennai 8
Curitiba 8
Dallas 8
Johannesburg 8
Munich 8
Seattle 8
Atlanta 7
Brooklyn 7
Denver 7
Dhaka 7
Poplar 7
Porto Alegre 7
San Mateo 7
Stockholm 7
Wilmington 7
Da Nang 6
Dearborn 6
Falkenstein 6
Moscow 6
Paris 6
Baghdad 5
Council Bluffs 5
Haiphong 5
Helsinki 5
Jeddah 5
Nanjing 5
Palermo 5
Rio de Janeiro 5
Abidjan 4
Amman 4
Amsterdam 4
Belo Horizonte 4
Bexley 4
Brasília 4
Buffalo 4
Cleveland 4
Hebei 4
Lappeenranta 4
London 4
Madrid 4
Messina 4
Mumbai 4
Phoenix 4
Portsmouth 4
Shanghai 4
Tianjin 4
Addis Ababa 3
Ankara 3
Augusta 3
Boardman 3
Bắc Ninh 3
Cairo 3
City of London 3
Cotia 3
Guaratinguetá 3
Guayaquil 3
Hải Dương 3
Jiaxing 3
Maceió 3
Montreal 3
Norwalk 3
Nova Iguaçu 3
Ottawa 3
Querétaro 3
Recife 3
Redwood City 3
São Gonçalo 3
Uberlândia 3
Totale 1.668
Salva come PNG Salva come JPEG
Nome #
Methylation study of the Paris system for reporting urinary (TPS) categories 134
Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine 130
DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group 127
Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers 119
Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives 119
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions 118
Biomarkers of response to advanced prostate cancer therapy 118
Faecal microbiota transplantation for the treatment of diarrhoea induced by tyrosine-kinase inhibitors in patients with metastatic renal cell carcinoma 111
PD-L1 Expression in de Novo Metastatic Castration-sensitive Prostate Cancer 107
PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: A systematic review and meta-analysis 105
Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients 104
The effect of a treatment delay on outcome in metastatic renal cell carcinoma 103
Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives 96
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study 94
Cabozantinib-related pneumothorax in rapidly responding patients with renal cell carcinoma 94
Comparison of PIV and Other Immune Inflammation Markers of Oncological and Survival Outcomes in Patients Undergoing Radical Cystectomy 92
Current evidence for second-line treatment in metastatic renal cell carcinoma after progression to immune-based combinations 90
Prostate cancer heterogeneity: Discovering novel molecular targets for therapy 89
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study 88
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma 84
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients with Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial 82
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 81
The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis 80
Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario 80
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: Results from a phase I/II open-label, multicenter study 79
New first-line immunotherapy-based combinations for metastatic renal cell carcinoma: A systematic review and network meta-analysis 78
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis 76
Revising PTEN in the era of immunotherapy: New perspectives for an old story 74
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 73
First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin 69
Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis 69
Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors 68
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study 54
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study 48
Totale 3.133
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.082
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.082
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20215 0 0 0 0 0 0 0 0 0 0 5 0
2021/202286 6 0 3 13 10 0 2 11 3 4 23 11
2022/2023258 54 42 13 25 30 14 17 19 26 2 10 6
2023/2024177 11 36 9 22 5 22 13 1 7 12 17 22
2024/2025702 6 4 33 10 18 18 69 30 77 124 154 159
2025/20261.842 282 90 131 310 359 80 264 114 109 103 0 0
Totale 3.133